3 terminated, 1 active not recruiting. 3 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Terminated 2, Active not recruiting 1 |
| Phase 2 | 3 | Terminated 2, Active not recruiting 1 |
Follow Mustang Bio: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL MB-106 - Follicular B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma Recurrent | Phase 1 / Phase 2 | Terminated | Mustang Bio | 20 | 2022-05-24 | 2024-07-22 |
| Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product. Prior MB-102 CAR-T cell investigational product., Prior MB-106 CAR-T cell investigational product. - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Chronic Lymphocytic Leukemia in Relapse | Terminated | Mustang Bio | 3 | 2021-09-29 | 2024-07-22 | |
| Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN. MB-102, Fludarabine, Cyclophosphamide - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Phase 1 / Phase 2 | Terminated | Mustang Bio | 3 | 2020-02-17 | 2024-07-22 |
| A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Laboratory Biomarker Analysis - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Active not recruiting | Fred Hutchinson Cancer Center | 53 | 2017-12-05 | 2026-06-22 |
Leukemia, Lymphocytic, Chronic, B-Cell (3) · Blastic Plasmacytoid Dendritic Cell Neoplasm (2) · Lymphoma, Large B-Cell, Diffuse (2) · Recurrence (2) · Leukemia, Hairy Cell (1) · Leukemia, Lymphoid (1) · Lymphoma, B-Cell (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, Non-Hodgkin (1)
Cyclophosphamide (2) · fludarabine phosphate (2) · Immunotherapy, Adoptive (1) · Leukapheresis (1) · fludarabine (1) · relmapirazin (1)
United States (4)
Bruce Dezube, M.D. (1) · Lihua E Budde, MD (1) · Mazyar Shadman (1) · Mazyar Shadman, MD (1)
R44CA265616 (1)